MYC dysregulation in the progression of multiple myeloma

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127

Multiple myeloma: evolving genetic events and host interactions

Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J. R., Barlogie, B., & Shaughnessy, J. D. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 700

A monoclonal gammopathy precedes multiple myeloma in most patients

Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568

MYC Deregulation in Primary Human Cancers

Kalkat, M., Melo, J. D., Hickman, K. A., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W. B., & Penn, L. Z. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 469

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

Affer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., Garbitt, V. M., Riggs, D. L., Brents, L. A., Roschke, A. V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.70 · Cited by 273

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

Walker, B. A., Wardell, C. P., Brioli, A., Boyle, E. M., Kaiser, M., Begum, D. B., Dahir, N. B., Johnson, D. C., Ross, F. M., Davies, F. E., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.13 · Cited by 182

MAX Inactivation in Small Cell Lung Cancer Disrupts MYC–SWI/SNF Programs and Is Synthetic Lethal with BRG1

Romero, O. A., Torres-Diz, M., Pros, E., Savola, S. P., Gómez, A., Morán, S., Sáez, C., Iwakawa, R., Villanueva, A., Montuenga, L. M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0799 · Cited by 164

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Barwick, B. G., Neri, P. E., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 147

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability

Dutta, A. K., Fink, J. L., Grady, J. P., Morgan, G. J., Mullighan, C. G., To, L. B., Hewett, D. R., & Zannettino, A. C. W. (2018) · Leukemia · doi:10.1038/s41375-018-0206-x · Cited by 140

Multiple myeloma

Malard, F., Neri, P. E., Bahlis, N. J., Terpos, E., Moukalled, N. M., Hungria, V., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 387

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00366-3 · Cited by 291

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R., & Safa, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01111-4 · Cited by 223

Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression

Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00437 · Cited by 187

Genomic profiling for clinical decision making in lymphoid neoplasms

de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A. J., Doǧan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., et al. (2022) · Blood · doi:10.1182/blood.2022015854 · Cited by 176

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Oben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., Yellapantula, V., Derkach, A., Geerdens, E., Diamond, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22140-0 · Cited by 129

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

Boyle, E. M., Deshpande, S., Tytarenko, R., Ashby, C., Wang, Y., Bauer, M. A., Johnson, S. K., Wardell, C. P., Thanendrarajan, S., Zangari, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20524-2 · Cited by 128

Revealing the Impact of Structural Variants in Multiple Myeloma

Rustad, E. H., Yellapantula, V. D., Głodzik, D., Maclachlan, K. H., Diamond, B. T., Boyle, E. M., Ashby, C., Blaney, P., Gundem, G., Hultcrantz, M. L., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0132 · Cited by 122

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

Cardona‐Benavides, I. J., Ramón, C. D., & Gutierrez, N. C. (2021) · Cells · doi:10.3390/cells10020336 · Cited by 107

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01853-0 · Cited by 95

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Vo, J. N., Wu, Y., Mishler, J., Hall, S., Mannan, R., Wang, L., Yu, N., Zhou, J. R., Hopkins, A. C., Estill, J. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31430-0 · Cited by 103

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Larráyoz, M., Garcia-Barchino, M. J., Celay, J., Etxebeste, A., Jiménez, M., Pérez, C., Ordóñez, R., Cobaleda, C., Botta, C., Fresquet, V., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02178-3 · Cited by 93

Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis

Boiarsky, R. P., Haradhvala, N. J., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M., Firer, D. T., Miller, M. L., El‐Khoury, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33944-z · Cited by 80

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.017 · Cited by 70

Accelerated single cell seeding in relapsed multiple myeloma

Landau, H. J., Yellapantula, V. D., Diamond, B. T., Rustad, E. H., Maclachlan, K. H., Gundem, G., Medina-Martinez, J. S., Ossa, J. A., Levine, M. F., Zhou, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17459-z · Cited by 72

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level

Schinke, C., Poos, A. M., Bauer, M., John, L., Johnson, S., Deshpande, S., Carrillo, L. F., Alapat, D. V., Rasche, L., Thanendrarajan, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007217 · Cited by 67

Chromosomal defects in multiple myeloma

Clarke, S. E., Fuller, K. A., & Erber, W. N. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101168 · Cited by 66

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?

Bolli, N., Genuardi, E., Ziccheddu, B., Martello, M., Oliva, S., & Terragna, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00189 · Cited by 57

Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence

Misund, K., Bruinink, D. H. O., Coward, E., Hoogenboezem, R. M., Rustad, E. H., Sanders, M. A., Rye, M. B., Sponaas, A., van der Holt, B., Zweegman, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01597-y · Cited by 56

FOXM1 regulates glycolysis and energy production in multiple myeloma

Cheng, Y., Sun, F., Thornton, K. A., Jing, X., Dong, J., Yun, G., Pisano, M. D., Zhan, F., Kim, S. H., Katzenellenbogen, J. A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02398-4 · Cited by 56

Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma

Abdallah, N. H., Baughn, L. B., Rajkumar, S. V., Kapoor, P., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dingli, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2283 · Cited by 55

Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma

Termini, R., Žihala, D., Terpos, E., Perez-Montaña, A., Jelínek, T., Raab, M., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1594 · Cited by 54

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

on behalf of the GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group, Garcés, J., Bretones, G., Burgos, L., Valdés‐Mas, R., Puig, N., Cedena, M., Alignani, D., Rodríguez, I., Puente, D. Á., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0883-0 · Cited by 54

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde

Musto, P., Engelhardt, M. M., Caers, J., Bolli, N., Kaiser, M., van de Donk, N. W. C. J., Terpos, E., Broijl, A., de Larrea, C. F., Gay, F., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278519 · Cited by 51

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

Robinson, M. H., Villa, N. Y., Jaye, D. L., Nooka, A. K., Duffy, A., McCachren, S. S., Manalo, J., Switchenko, J. M., Barnes, S., Potdar, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167629 · Cited by 48

Evolution and structure of clinically relevant gene fusions in multiple myeloma

Foltz, S. M., Gao, Q., Yoon, C. J., Sun, H., Yao, L., Li, Y., Jayasinghe, R. G., Cao, S., King, J. A., Kohnen, D. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16434-y · Cited by 48

Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

Welsh, S. J., Barwick, B. G., Meermeier, E. W., Riggs, D. L., Shi, C.-X., Zhu, Y. X., Sharik, M. E., Du, M. T., Rocha, L. D. A., Garbitt, V. M., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0062 · Cited by 44

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Shen, Y. J., Mishima, Y., Shi, J., Sklavenitis‐Pistofidis, R., Redd, R. A., Moschetta, M., Manier, S., Roccaro, A. M., Sacco, A., Tai, Y., et al. (2020) · Blood · doi:10.1182/blood.2020005885 · Cited by 44

Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma

Gonsalves, W. I., Broniowska, K. A., Jessen, E., Petterson, X.-M. T., Bush, A. G., Gransee, J., Lacy, M. Q., Hitosugi, T., & Kumar, S. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-67105-3 · Cited by 42

TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B-cell malignancies.

Li, C., Xia, J.-L., Machin, R. F., Chen, F.-P., He, Y.-J., Ashby, T., Teng, F., Xu, H.-W., Liu, D.-X., Gai, D.-Z., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146893 · Cited by 39

MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology

Dutta, A. K., Alberge, J.-B., Lightbody, E. D., Boehner, C. J., Dunford, A., Sklavenitis-Pistofidis, R., Mouhieddine, T. H., Cowan, A. N., Su, N. K., Horowitz, E. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0482 · Cited by 41

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Ansari‐Pour, N., Samur, M., Flynt, E., Gooding, S., Towfic, F., Stong, N., Estévez, M. O., Mavrommatis, K., Walker, B. A., Morgan, G. J., et al. (2022) · Blood · doi:10.1182/blood.2022017010 · Cited by 40

Genome Instability in Multiple Myeloma: Facts and Factors

Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 43

Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities

Kriegová, E., Fillerová, R., Minařík, J., Savara, J., Manakova, J., Petráčková, A., Dihel, M., Balcárková, J., Krhovská, P., Pika, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93835-z · Cited by 41

Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression

Chesi, M., Stein, C. K., Garbitt, V. M., Sharik, M. E., Asmann, Y. W., Bergsagel, M., Riggs, D. L., Welsh, S. J., Meermeier, E. W., Kumar, S. K., et al. (2020) · Blood Cancer Discovery · doi:10.1158/0008-5472.bcd-19-0068 · Cited by 38

Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma

Smadbeck, J. B., Peterson, J. F., Pearce, K. E., Pitel, B. A., Figueroa, A. L., Timm, M., Jevremović, D., Shi, M., Stewart, A. K., Braggio, E., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0255-z · Cited by 37

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma

Sharma, N., Smadbeck, J. B., Abdallah, N. H., Zepeda‐Mendoza, C. J., Binder, M., Pearce, K. E., Asmann, Y. W., Peterson, J. F., Ketterling, R. P., Greipp, P. T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0005 · Cited by 37

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Bustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30694-w · Cited by 35

Super-enhancers: A new frontier for glioma treatment

Cheng, M., Zhang, Z. W., Ji, X., Xu, Y., Bian, E., & Zhao, B. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188353 · Cited by 35

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics

Awada, H. K., Thapa, B., Awada, H., Dong, J., Gurnari, C., Hari, P., & Dhakal, B. (2021) · Cells · doi:10.3390/cells10081961 · Cited by 35

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma

Neri, P. E., Barwick, B. G., Jung, D., Patton, J. C., Maity, R., Tagoug, I., Stein, C. K., Tilmont, R., Leblay, N., Ahn, S., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0061 · Cited by 35

Pathway-Directed Therapy in Multiple Myeloma

John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 33

Genomic landscape of multiple myeloma and its precursor conditions

Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02196-0 · Cited by 32

New horizons in our understanding of precursor multiple myeloma and early interception

dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 34

Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma

Bloedjes, T. A., de Wilde, G., & Guikema, J. E. J. (2021) · Cancers · doi:10.3390/cancers13030396 · Cited by 32

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma

Caracciolo, D., Riillo, C., Juli, G., Scionti, F., Todoerti, K., Polerà, N., Grillone, K., Fiorillo, L., Arbitrio, M., Martino, M. T. D., et al. (2021) · Cancers · doi:10.3390/cancers13174365 · Cited by 31

Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression

Croucher, D. C., Richards, L. M., Tsofack, S. P., Waller, D. D., Li, Z., Wei, E. N., Huang, X. F., Chesi, M., Bergsagel, P. L., Sébag, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26598-w · Cited by 30

Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup

Wiedmeier, J. E., & Bergsagel, P. L. (2022) · Life · doi:10.3390/life12060812 · Cited by 30

Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy

Nair, R., Gupta, P., & Shanmugam, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1000106 · Cited by 29

Lipid metabolic vulnerabilities of multiple myeloma

Torcasio, R., Cantafio, M. E. G., Ikeda, R. K., Ganino, L., Viglietto, G., & Amodio, N. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01174-2 · Cited by 28

Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma

Giguère, A., Raymond‐Bouchard, I., Collin, V., Claveau, J., Hébert, J., & LeBlanc, R. (2023) · Cancers · doi:10.3390/cancers15194687 · Cited by 27

Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events

Landgren, O. (2021) · Hematology · doi:10.1182/hematology.2021000303 · Cited by 30

Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma

Maura, F., Landgren, O., & Morgan, G. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1395 · Cited by 28

sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution

Mahdipour–Shirayeh, A., Erdmann, N., Leung-Hagesteijn, C., & Tiedemann, R. E. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab413 · Cited by 25

Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group

Lu, X., Andersen, E., Banerjee, R. K., Eno, C., Gonzales, P. R., Kumar, S. K., Lager, A. M., Miron, P. M., Pugh, T. J., Quintero‐Rivera, F., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01286-w · Cited by 24

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma

Sudha, P., Ahsan, A., Ashby, C., Kausar, T., Khera, A., Kazeroun, M. H., Hsu, C.-C., Wang, L., Fitzsimons, E., Salminen, O., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3695 · Cited by 28

A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity

Vià, M. D., Ziccheddu, B., Maeda, A., Bagnoli, F., Perrone, G., & Bolli, N. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000502 · Cited by 27

The Role of Epigenetics in the Development and Progression of Multiple Myeloma

Ismail, N. H., Mussa, A., Zakaria, N. A., Al-Khreisat, M. J., Zahidin, M. A., Ramli, N. N., Mohammad, S. N. N. A., Hassan, R., Mohd Noor, N. H., Iberahim, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112767 · Cited by 22

The Molecular Pathogenesis of Multiple Myeloma

Bolli, N., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.9054 · Cited by 22

Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies

Visram, A., Cook, J., & Warsame, R. M. (2021) · Hematology · doi:10.1182/hematology.2021000304 · Cited by 26

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma

Ortiz-Ruiz, A., Ruiz‐Heredia, Y., Morales, M. L., Aguilar-Garrido, P., García-Ortiz, A., Valeri, A., Bárcena, C., García-Martín, R., Garrido, V., Moreno, L., et al. (2021) · Cancers · doi:10.3390/cancers13071662 · Cited by 22

Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing

Fitzpatrick, M. J., Nardi, V., & Sohani, A. R. (2021) · Skeletal Radiology · doi:10.1007/s00256-021-03754-3 · Cited by 22

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55308-5 · Cited by 20

Molecular Pathogenesis of Multiple Myeloma

Maura, F., & Bergsagel, P. L. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.010 · Cited by 19

Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma

Bruno, T., Nicola, F. D., Corleone, G., Catena, V., Goeman, F., Pallocca, M., Sorino, C., Bossi, G., Amadio, B., Cigliana, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002566 · Cited by 20

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma

Giacomini, A., Taranto, S., Gazzaroli, G., Faletti, J., Capoferri, D., Marcheselli, R., Sciumé, M., Presta, M., Sacco, A., & Roccaro, A. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03217-2 · Cited by 19

Genomics define malignant transformation in myeloma precursor conditions

Maura, F., Bergsagel, P. L., Ziccheddu, B., Kumar, S., Maclachlan, K., Derkach, A., Garces, J.-J., Firestone, R., Braggio, E., Asmann, Y., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01733 · Cited by 18

The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans

Maura, F., Coffey, D. G., Stein, C. K., Braggio, E., Ziccheddu, B., Sharik, M. E., Du, M. T., Alvarado, Y. T., Shi, C.-X., Zhu, Y. X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48091-w · Cited by 18

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance

Davis, L. N., Walker, Z. J., Reiman, L. T., Parzych, S. E., Stevens, B. M., Jordan, C. T., Forsberg, P. A., & Sherbenou, D. W. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0256 · Cited by 17

Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma

Barwick, B. G., Gupta, V. A., Matulis, S. M., Patton, J. C., Powell, D. R., Gu, Y., Jaye, D. L., Conneely, K. N., Lin, Y. C., Hofmeister, C. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2931 · Cited by 17

Section E6.1–6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes

Akkari, Y. M. N., Baughn, L. B., Kim, A., Karaca, E., Raca, G., Shao, L., & Mikhail, F. M. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2023.101054 · Cited by 16

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets

Petrusca, D. N., Lee, K. P., & Galson, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925807 · Cited by 16

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance

Saldarriaga, M. M., Darwiche, W., Jayabalan, D. S., Monge, J., Rosenbaum, C. A., Pearse, R. N., Niesvizky, R., & Bustoros, M. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020011 · Cited by 16

Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma

Saade, C., & Ghobrial, I. M. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104268 · Cited by 15

Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models

Kunz, V., Bommert, K. S., Kruk, J., Schwinning, D., Chatterjee, M., Stühmer, T., Bargou, R. C., & Bommert, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-75499-3 · Cited by 15

Temporal genomic dynamics shape clinical trajectory in multiple myeloma

Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02292-1 · Cited by 14

WDR26 and MTF2 are therapeutic targets in multiple myeloma

Sun, F., Cheng, Y., Riordan, J. D., Dupuy, A. J., Dubois, W., Pisano, M. D., Dong, J., Mock, B. A., Zhan, F., Hari, P., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01217-9 · Cited by 14

The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance

Zou, J., Jones, R. J., Wang, H., Kuiatse, I., Shirazi, F., Manasanch, E. E., Lee, H. C., Sullivan, R., Fung, L. M., Richard, N., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01943-6 · Cited by 14

Pathogenic signaling in multiple myeloma

Bolomsky, A., & Young, R. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.005 · Cited by 15

Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways

Saadoune, C., Nouadi, B., Hamdaoui, H., Chegdani, F., & Bennis, F. (2022) · Bioinformatics and Biology Insights · doi:10.1177/11779322221115545 · Cited by 13

MYC alterations in multiple myeloma: Genetic insights and prognostic impact

Cristobal‐Vargas, S., Cuadrado, M., & Gutierrez, N. C. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101177 · Cited by 12

Genetic Predictors of Mortality in Patients with Multiple Myeloma

Hassan, H., & Szalat, R. E. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s262866 · Cited by 12

High or low? Assessing disease risk in multiple myeloma

Schmidt, T. M. (2022) · Hematology · doi:10.1182/hematology.2022000347 · Cited by 12

Myeloma and DNA damage

Tonon, G. (2023) · Blood · doi:10.1182/blood.2023021384 · Cited by 11

SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors

Lightbody, E. D., Sklavenitis‐Pistofidis, R., Wu, T., Tsuji, J., Firer, D. T., Agius, M. P., Dutta, A. K., Barr, H., Kim, S., Alberge, J.-B., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01006-0 · Cited by 12

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

Ruiz‐Heredia, Y., Ortiz-Ruiz, A., Samur, M., Garrido, V., Rufián, L., Sánchez, R., Aguilar-Garrido, P., Barrio, S., Martín, M. A., Bolli, N., et al. (2021) · Cancers · doi:10.3390/cancers13133189 · Cited by 11

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma

Peat, T. J., Gaikwad, S. M., Dubois, W., Gyabaah-Kessie, N., Zhang, S., Gorjifard, S., Phyo, Z. H., Andres, M., Hughitt, V. K., Simpson, R. J., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216284 · Cited by 10

What Is New in the Treatment of Smoldering Multiple Myeloma?

Bolli, N., Sgherza, N., Curci, P., Rizzi, R., Strafella, V., Delia, M., Gagliardi, V. P., Neri, A., Baldini, L., Albano, F., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030421 · Cited by 10

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells

Byrgazov, K., Bešše, A., Kraus, M., Slipicevic, A., Lehmann, F., Driessen, C., & Bešše, L. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000602 · Cited by 10

Selective Enhancer Gain-of-Function Deregulates MYC Expression in Multiple Myeloma

Rahmat, M., Clement, K., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Kodgule, R., Fulco, C. P., Heilpern-Mallory, D., Nilsson, K., Dorfman, D. M., Engreitz, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1440 · Cited by 10

Genomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?

Botrugno, O. A., & Tonon, G. (2021) · Cancers · doi:10.3390/cancers14010025 · Cited by 9

Evolution of Multiple Myeloma from a Genomic Perspective

Maura, F., Samur, M., & Munshi, N. (2026) · Blood · doi:10.1182/blood.2024026313 · Cited by 8

Eμ and 3′RR transcriptional enhancers of the IgH locus cooperate to promote c-myc–induced mature B-cell lymphomas

Ghazzaui, N., Issaoui, H., Ferrad, M., Carrion, C., Cook‐Moreau, J., Denizot, Y., & Boyer, F. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000845 · Cited by 8

Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions

Chojnacka, M., Diamond, B. T., Landgren, O., & Maura, F. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.006 · Cited by 8

IL-32 is induced by activation of toll-like receptors in multiple myeloma cells

Aass, K. R., Tryggestad, S. S., Mjelle, R., Kastnes, M. H., Nedal, T. M. V., Misund, K., & Standal, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107844 · Cited by 8

Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma

Mehra, N., Sundaram, S., Shah, P. S., & Rao, A. K. D. M. (2025) · Current Oncology Reports · doi:10.1007/s11912-024-01623-5 · Cited by 8

The perspectives of interleukin-10 in the pathogenesis and therapeutics of multiple myeloma

Liu, C., Chang, C., & Huang, W. (2020) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_141_20 · Cited by 8

Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation

Maneix, L., Iakova, P. A., Moree, S. E., Hsu, J. I., Mistry, R. M., Stossi, F., Lulla, P., Sun, Z., Sahin, E., Yellapragada, S. V., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0255 · Cited by 8

Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups

Boyle, E. M., Rosenthal, A., Ghamlouch, H., Wang, Y., Farmer, P., Rutherford, M., Ashby, C., Bauer, M., Johnson, S., Wardell, C. P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01379-y · Cited by 8

Advancements in Multiple Myeloma Research: High-Throughput Sequencing Technologies, Omics, and the Role of Artificial Intelligence

Gutiérrez‐González, A., del Hierro, I., & Cariaga-Martínez, A. E. (2024) · Biology · doi:10.3390/biology13110923 · Cited by 7

MicroRNA signatures characterize multiple myeloma patients

Corthals, S. L., Sun, S. M., Kuiper, R., de Knegt, Y., Broyl, A., van der Holt, B., Beverloo, H. B., Peeters, J. K., el Jarari, L., Lokhorst, H. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.147 · Cited by 56

Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis

Boiarsky, R. P., Haradhvala, N. J., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M., Firer, D. T., Miller, M. L., El‐Khoury, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33944-z · Cited by 80

Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma

Qu, X., Sun, Z., Li, Y., Ying, W., Liu, Y., Wang, C., Hu, N., Tohetuoxun, S., Tong, D., Liu, H., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(25)04020-0

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease

Dang, M., Han, G., Lee, H. C., Patel, K. K., Becnel, M. R., Wang, R., Thomas, S. K., Hao, D., Chu, Y., Weber, D. M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.007 · Cited by 55

Single-cell analysis unveils distinct transcriptional alterations and cellular origins in IgD multiple myeloma

Luo, T., Zhou, X., Chen, X., Jin, L., Yang, Y., Hu, X., Li, J., & Du, J. (2025) · Haematologica · doi:10.3324/haematol.2025.288418